Show simple item record

dc.contributor.authorRuiz-Patiño, Alejandro
dc.contributor.authorBarrón, Feliciano
dc.contributor.authorCardona, Andrés F
dc.contributor.authorCorrales, Luis
dc.contributor.authorMas, Luis
dc.contributor.authorMartín, Claudio
dc.contributor.authorZatarain-Barrón, Zyanya L
dc.contributor.authorRecondo, Gonzalo
dc.contributor.authorRicaurte, Luisa
dc.contributor.authorRojas, Leonardo
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez, July
dc.contributor.authorSotelo, Carolina
dc.contributor.authorViola, Lucia
dc.contributor.authorVargas, Carlos
dc.contributor.authorCarranza, Hernán
dc.contributor.authorOtero, Jorge
dc.contributor.authorPino, Luis E
dc.contributor.authorRolfo, Christian
dc.contributor.authorRosell, Rafael
dc.contributor.authorArrieta, Oscar
dc.date.accessioned2020-08-05T17:16:07Z
dc.date.available2020-08-05T17:16:07Z
dc.date.issued2020-07-24
dc.identifier.urihttp://hdl.handle.net/10713/13477
dc.description.abstractBackground: The intestinal microbiota is an important factor in modulating immune-mediated tumor cell destruction. Alterations in the microbiome composition have been linked to reduced efficacy of immune checkpoint inhibitor (ICI) therapies. Therefore, antibiotic treatment (ATB), which modifies the diversity of the gut bacteria populations, could lead to a reduced efficacy of ICI treatments. Methods: This was a retrospective cohort study. Patients with advanced non-small cell lung cancer (NSCLC) treated with anti-programmed cell death ligand-1 (PD-L1) alone, or in combination in three different countries in Latin America were included. After identification, patients were placed into three groups: Non-ATB exposed (no-ATB), exposed within 30 days of the first dose of ICI (pre-ICI ATB) and patients receiving ATB concomitantly with ICI (ICI-ATB). Progression-free survival (PFS), overall survival (OS) and response rates to treatment with ICI were assessed. Results: A total of 140 patients were included, of which 32 patients (23%) received ATB treatment. The most common ATB types were fluoroquinolones and B-lactams. No differences in survival according to antibiotic type were identified. Median OS in patients not exposed to ATB was 40.6 months (95% CI: 32–67.7), compared with 20.3 months (95% CI: 12.1-non-reached [NR]) for patients with pre-ICI ATB treatment and 24.7 months (95% CI: 13-NR) for patients treated with ATB concomitantly with ICI. There were no significant differences in terms of PFS, or response rates across all treatment groups. Conclusions: Antibiotic treatment was associated with reduced OS in Hispanic patients with NSCLC treated with ICIs. © 2020 The Authors.en_US
dc.description.urihttps://doi.org/10.1111/1759-7714.13573en_US
dc.language.isoen_USen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofThoracic Canceren_US
dc.rights© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.en_US
dc.subjectAntibioticsen_US
dc.subjectimmunotherapyen_US
dc.subjectlung canceren_US
dc.titleAntibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP)en_US
dc.typeArticleen_US
dc.identifier.doi10.1111/1759-7714.13573
dc.identifier.pmid32705787
dc.source.countrySingapore


This item appears in the following Collection(s)

Show simple item record